Overview

Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

Status:
Terminated
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to study alternative treatments for the skin disease pemphigus (a rare autoimmune blistering disorder of the skin) by using sirolimus, an immunosuppressive drug. Immunosuppressive drugs inhibit or prevent the activity of the immune system and are commonly used to treat autoimmune diseases, inflammatory diseases, and organ transplantation rejection.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of California, Irvine
Treatments:
Everolimus
Sirolimus